Rebagit tablets are coated. 100 mg, 30 pcs.

(0) Write a Review

Product Description


1 tab.:
rebamipide 100 mg.
mannitol - 35.7 mg,
croscarmellose sodium - 14 mg,
pregelatinized starch - 80.7 mg,
sodium lauryl sulfate - 2 mg,
citric acid - 2.3 mg,
purified talc - 3.1 mg,
magnesium stearate - 2.2 mg.
The composition of the film shell:
hypromellose - 2.77 mg,
purified talc - 0.57 mg,
titanium dioxide - 1.11 mg,
propylene glycol - 0.55 mg.

pharmachologic effect

Clinical and pharmacological group:
Pharmacotherapeutic group :
Gastroprotective agent
pharmachologic effect
Rebamipid increases the content of prostaglandin E2 (PGE2) in the gastric mucosa and increases the content of PGE2 and GI2 in the contents of gastric juice. It has a cytoprotective effect against the gastric mucosa with the damaging effects of ethanol, acids and alkalis, acetylsalicylic acid.
It promotes the activation of enzymes that accelerate the biosynthesis of high molecular weight glycoproteins, and increases the content of mucus on the surface of the stomach wall. It helps to improve the blood supply to the gastric mucosa, activates its barrier function, activates the alkaline secretion of the stomach, enhances the proliferation and metabolism of gastric epithelial cells, cleans the mucosa of hydroxyl radicals and suppresses superoxides produced by polymorphonuclear leukocytes and neutrophils in the presence of Helicobacter pylori, protects the mucosa from mucosa, protects the mucosa from mucosal infections has a gastroprotective effect when exposed to the mucosa of NSAIDs.
Suction and distribution
After administration at a dose of 100 mg, Cmax is reached after approximately 2 hours and is 340 ng / ml. Repeated doses of the drug do not lead to its cumulation in the body.
In vitro experiments have shown that from 98.4% to 98.6% of the drug binds to plasma proteins.
Metabolism and excretion of
T1 / 2 is approximately 1.0 hour. Approximately 10% of the drug is excreted by the kidneys, mainly unchanged. When taken in a dose of 600 mg, traces of a hydroxylated metabolite can be distinguished.


- stomach ulcer;
- chronic gastritis with increased acid-forming function of the stomach in the acute phase, erosive gastritis;
- prevention of damage to the mucous membrane while taking NSAIDs;
It can be used as part of combination therapy.


- individual intolerance to ribamipid or other components of the drug;
- pregnancy;
- lactation period;
- age up to 18 years.

Side effects

From the digestive system: constipation, flatulence, diarrhea, nausea, vomiting, pain in the abdomen, violation of taste sensations, heartburn.
From the liver: signs of liver dysfunction, increased serum ALT and ACT.
From the hemopoietic system: leukopenia, granulocytopenia.
Other: menstrual irregularities.


When using rebamipide as part of traditional treatment regimens for patients with Helicobacter pylori infection, the effectiveness of eradication therapy significantly increases.
Reactions with other drugs have not been studied.

How to take, course of administration and dosage

Inside, 1 tablet 3 times / day, washed down with a small amount of liquid.
The course of treatment is 2-4 weeks, if necessary, can be extended up to 8 weeks.
The drug does not have action features at the first dose or when it is canceled.
If you skip taking one dose, you must take the next dose of the drug at the prescribed time, you should not take a double dose of the drug.


Symptoms of an overdose of rebamipide have not been described; to date, there have been no reports of deliberate overdose.
Nausea, vomiting, abdominal pain, diarrhea or constipation, headache are possible.

Treatment: specific antidote unknown.
In case of an overdose, the stomach should be washed and symptomatic therapy should be carried out.

Special instructions

The safety of rebamipide during pregnancy has not been proven. Do not use during pregnancy.
Since rebamipid is excreted in breast milk, breast-feeding should be discontinued or the issue of artificial feeding of the baby should be resolved if it is necessary to prescribe rebamipid to the mother during lactation.
Use in children
Contraindicated in children under 18 years of age.
Use in elderly patients
At the first appointment of rebamipide to patients from old age due to the possibility of increased sensitivity to the drug.
Impact on the ability to drive vehicles and mechanisms
The effect of the drug on the speed of psychomotor reactions and / or the ability to drive vehicles or mechanisms has not been studied. In the case of taking the drug, you should be careful about driving a car and other activities that require an increased concentration of attention.

Release form

Film-coated tablets of white or almost white color, round, biconvex.

Storage conditions

The drug should be stored out of the reach of children, dry, protected from light, at a temperature not exceeding 25 ° C. 

Shelf life

2 years.

Customers Also Viewed